Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

ThermalTherapeutic Systems, Applied Medical enter strategic alliance

ThermalTherapeutic Systems, Inc., the developer of a highly portable platform technology designed to standardize hyperthermic perfusion treatments, today announced a strategic alliance with Applied Medical Products and Solutions of Boston, MA.

25 Oct 2010

CryoLife commences European distribution of PerClot polysaccharide hemostatic agent

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has begun European distribution of PerClot®, a novel polysaccharide hemostatic agent used to control bleeding during surgical procedures or following traumatic injuries.

25 Oct 2010

NeedleTech increases production area with new 73,000-square foot manufacturing facility

U.S. Congressman James McGovern, State Representative Elizabeth Poirier and local dignitaries joined Theragenics Corporation executives in ribbon cutting ceremonies on October 15 for a new 73,000-square foot manufacturing facility for the company's subsidiary, NeedleTech Products. The new facility increases NeedleTech's production area by 30% or 20,000 square feet, allowing the company to consolidate two separate older facilities into one location. The new building will allow NeedleTech to expand operations, increase R&D and offer more services to its customers.

25 Oct 2010

Biomerix enters distribution agreement with Medline

Biomerix Corporation, a medical technology company developing and manufacturing innovative hernia repair products, today announced that it has entered into an exclusive distribution agreement with Medline Industries, Inc., the nation's largest privately held manufacturer and distributor of medical and surgical products in the United States.

25 Oct 2010

FDA warns about risk of Hyland's Teething Tablets to children

The U.S. Food and Drug Administration today is warning consumers that Hyland's Teething Tablets may pose a risk to children. The FDA recommends that consumers not use this product and dispose of any in their possession. The manufacturer is issuing a recall of this product.

25 Oct 2010

VTI expands into consumer electronics segment

VTI Technologies, a pioneer in Micro-Electro-Mechanical Systems (MEMS) for the past 20 years, is now taking a new direction and expanding into the consumer electronics segment. VTI is already the market leader in low-g sensors for the automotive industry, as well as in ultra-low power sensors for the medical implantable market.

25 Oct 2010

FDA issues complete response letter for ViroPharma's Cinryze

ViroPharma Incorporated today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities. The FDA has requested additional information related to observations from the pre-approval inspection and review of the technical processes.

25 Oct 2010

Research project on food allergy to showcase results at symposium in Nice

A research project on food allergy that involved 25 countries worldwide will showcase some of its results at a symposium in Nice starting today. "What we found won't make it easy to pinpoint which foods carry the biggest risk, as the risk for individual foods varies from country to country," says project coordinator Professor Clare Mills from the Institute of Food Research.

22 Oct 2010

Occlutech receives favorable appeal court ruling against patent litigation with AGA Medical

Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable appeal court ruling from The Hague, The Netherlands in the on-going patent litigation with AGA Medical. A favourable first instance court ruling obtained by Occlutech had been appealed by AGA in 2008.

22 Oct 2010

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that it has been awarded a $4.99 million contract to assist the U.S. Army Medical Research Institute for Infectious Diseases in its vaccine development efforts.

22 Oct 2010

New York Times Magazine examines individual-initiated foreign aid projects

A New York Times Magazine article by the newspaper's Op-Ed columnist Nicolas Kristof examines a "revolution" that is "just beginning" and "might be called Do-It-Yourself Foreign Aid, because it starts with the proposition that it's not only presidents and United Nations officials who chip away at global challenges. Passionate individuals with great ideas can do the same, especially in the age of the Internet and social media."

22 Oct 2010

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.

22 Oct 2010

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.

21 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Nonprescription drug manufacturing and marketing costs increase: Kline

A number of costs associated with nonprescription drug manufacturing and marketing have increased over the past two and a half years. Certain material costs for plastic bottles and blister packs have risen by double digits during this time, increasing packaging expenses.

21 Oct 2010

Vascular Solutions acquires EXPRO Elite and MICRO Elite snare products from Radius

Vascular Solutions, Inc. today announced that it has acquired the assets related to the EXPRO Elite™ and MICRO Elite™ snare products from Radius Medical Technologies, Inc. and its subsidiary, Radius Medical, LLC. Vascular Solutions has been selling the EXPRO Elite™ and MICRO Elite™ snares in the U.S. under a distribution relationship with Radius since 2008, while in international markets Radius has been selling the products through a network of independent distributors.

21 Oct 2010

Victorian Government grants assist companies build global markets

The Brumby Labor Government is providing $410,000 in grants to help three Melbourne companies improve their global competitiveness, save money on production costs and create local jobs.

21 Oct 2010

FDA issues complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON™ (exenatide extended-release for injectable suspension).

21 Oct 2010

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

21 Oct 2010

Cipla launches generic Pirfenidone for IPF

Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers. Till now there is no approved treatment for IPF.

20 Oct 2010